Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway

Endocrinology

Volumn 141, Issue 6, 2000, Pages 2257-2265

  Miyake, Hideaki ^b   Nelson, Colleen ^b   Rennie, Paul S ^b   Gleave, Martin E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CYCLIN D1; DNA FRAGMENT; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; CANCER GROWTH; CASTRATION; CELL CYCLE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; MITOGENICITY; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 0034455310     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.6.7520     Document Type: Article

References (44)

1. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
2. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system
3. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer
4. Target to apoptosis: A hopeful weapon for prostate cancer
5. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
6. c-Jun can mediate androgen receptor-induced transactivation
7. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP
8. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
9. Insulin-like growth factors and their binding proteins: Biological actions
10. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions
11. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition
12. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action
13. An insulin-like growth factor (IGF) binding protein enhances the biological response to IGF-I
14. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
15. Insulin-llke growth factor-binding proteins (IGFBPs) and their regulatory dynamics
16. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5
17. Insulin-like growth factor binding protein 5 is associated with involution of the ventral prostate in castrated and finasteride-treated rats
18. Regulation of insulin like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analogue EB1089
19. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3
20. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft
21. Insulinlike growth factor binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization
22. Insulin-like growth factor binding protein-2 and -3 expression in benign human prostprostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate
23. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer
24. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism
25. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation
26. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts
27. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors
28. Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal-stripped media
29. Insulin-like growth factor (IGF) system components in human prostatic cancer cell lines: LNCaP, DU145, and PC-3 cells
30. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer
31. Antisense Bcl-2 olgodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model
32. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1
33. p42/p44 mitogen-activated protein kinases activation is required for the insulin-like growth factor-I/insulin induced proliferation, but inhibits differentiation, in rat fetal brown adipocytes
34. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I
35. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcInoma cells by MMAC/PTEN
36. Inhibition of growth of prostatic cell lines by peptide analogues of insulin-like growth factor 1
37. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3)
38. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study
39. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
40. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins
41. Regulation of insulin-like growth factor binding protein-5 messenger ribonucleic acid expression and protein availability in rat osteoblast-like cells
42. Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5
43. Extracellular matrix contains insulin-like growth factor binding protein-5:potentiation of the effects of IGF-I
44. Carboxy-truncated insulin-like growth factor binding protein-5 stimulates mitogenesis in osteoblast-like cells